Galleon Pharmaceuticals develops medicines to treat disrupted breathing control, with primary targets including sleep apnea, COPD, ventilator weaning, drug-induced respiratory depression, and obesity-related hypoventilation. The company was founded in 2003 by CEO and President James C. Mannion, who has more than two decades of pharmaceutical and clinical development experience. Early technology was licensed from the University of Louisville in 2006, based on work by Dr. David Gozal. Galleon has pursued a drug strategy that includes a patented combination involving S‑Nitrosothiol intended to trigger normal low‑oxygen respiratory responses. The company has operated largely in stealth mode while advancing its programs. Financially, Galleon launched with a $500,000 seed investment in 2005, closed a $15 million B round in December 2008, and recently raised $10 million to support its discovery efforts.

Total raised

$10M

Funding rounds

1

Latest round

Equity

Latest activity

Nov 2010